ISPECIMEN INC (ISPC) Stock Fundamental Analysis

NASDAQ:ISPC • US45032V2079

0.3184 USD
+0.01 (+2.78%)
At close: Feb 12, 2026
0.3018 USD
-0.02 (-5.21%)
After Hours: 2/12/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ISPC. ISPC was compared to 35 industry peers in the Health Care Technology industry. The financial health of ISPC is average, but there are quite some concerns on its profitability. ISPC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ISPC has reported negative net income.
  • ISPC had a negative operating cash flow in the past year.
  • In the past 5 years ISPC always reported negative net income.
  • ISPC had a negative operating cash flow in each of the past 5 years.
ISPC Yearly Net Income VS EBIT VS OCF VS FCFISPC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • The Return On Assets of ISPC (-128.18%) is worse than 88.57% of its industry peers.
  • The Return On Equity of ISPC (-375.34%) is worse than 82.86% of its industry peers.
Industry RankSector Rank
ROA -128.18%
ROE -375.34%
ROIC N/A
ROA(3y)-81.82%
ROA(5y)-69.08%
ROE(3y)-180.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISPC Yearly ROA, ROE, ROICISPC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

  • The Gross Margin of ISPC (21.29%) is worse than 80.00% of its industry peers.
  • In the last couple of years the Gross Margin of ISPC has declined.
  • ISPC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.72%
GM growth 5Y-3.19%
ISPC Yearly Profit, Operating, Gross MarginsISPC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ISPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ISPC has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ISPC has been reduced compared to 5 years ago.
  • ISPC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ISPC Yearly Shares OutstandingISPC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ISPC Yearly Total Debt VS Total AssetsISPC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • ISPC has an Altman-Z score of -16.08. This is a bad value and indicates that ISPC is not financially healthy and even has some risk of bankruptcy.
  • ISPC has a Altman-Z score of -16.08. This is amonst the worse of the industry: ISPC underperforms 94.29% of its industry peers.
  • ISPC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.08
ROIC/WACCN/A
WACC9.54%
ISPC Yearly LT Debt VS Equity VS FCFISPC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • ISPC has a Current Ratio of 0.63. This is a bad value and indicates that ISPC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.63, ISPC is doing worse than 88.57% of the companies in the same industry.
  • ISPC has a Quick Ratio of 0.63. This is a bad value and indicates that ISPC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.63, ISPC is doing worse than 88.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.63
ISPC Yearly Current Assets VS Current LiabilitesISPC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • ISPC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.29%, which is quite impressive.
  • The Revenue for ISPC has decreased by -67.73% in the past year. This is quite bad
  • Measured over the past years, ISPC shows a quite strong growth in Revenue. The Revenue has been growing by 16.66% on average per year.
EPS 1Y (TTM)63.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.27%
Revenue 1Y (TTM)-67.73%
Revenue growth 3Y-5.87%
Revenue growth 5Y16.66%
Sales Q2Q%-95.99%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y10.23%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ISPC Yearly Revenue VS EstimatesISPC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
ISPC Yearly EPS VS EstimatesISPC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ISPC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ISPC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ISPC Price Earnings VS Forward Price EarningsISPC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ISPC Per share dataISPC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ISPC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ISPECIMEN INC

NASDAQ:ISPC (2/12/2026, 8:00:02 PM)

After market: 0.3018 -0.02 (-5.21%)

0.3184

+0.01 (+2.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-14
Earnings (Next)N/A
Inst Owners3.51%
Inst Owner Change1.88%
Ins Owners0.26%
Ins Owner Change0%
Market Cap3.11M
Revenue(TTM)3.35M
Net Income(TTM)-11.53M
Analysts82.86
Price TargetN/A
Short Float %3.21%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.93
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.95
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0.34
BVpS0.31
TBVpS-0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -128.18%
ROE -375.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.29%
FCFM N/A
ROA(3y)-81.82%
ROA(5y)-69.08%
ROE(3y)-180.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.72%
GM growth 5Y-3.19%
F-Score2
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.37%
Cap/Sales 32.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.63
Altman-Z -16.08
F-Score2
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)173.33%
Cap/Depr(5y)151.75%
Cap/Sales(3y)28.61%
Cap/Sales(5y)21.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.27%
EPS Next Y10.23%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-67.73%
Revenue growth 3Y-5.87%
Revenue growth 5Y16.66%
Sales Q2Q%-95.99%
Revenue Next Year11.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.43%
OCF growth 3YN/A
OCF growth 5YN/A

ISPECIMEN INC / ISPC FAQ

What is the ChartMill fundamental rating of ISPECIMEN INC (ISPC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ISPC.


What is the valuation status for ISPC stock?

ChartMill assigns a valuation rating of 0 / 10 to ISPECIMEN INC (ISPC). This can be considered as Overvalued.


What is the profitability of ISPC stock?

ISPECIMEN INC (ISPC) has a profitability rating of 0 / 10.


What is the expected EPS growth for ISPECIMEN INC (ISPC) stock?

The Earnings per Share (EPS) of ISPECIMEN INC (ISPC) is expected to grow by 10.23% in the next year.